Published in N Engl J Med on November 15, 2011
CRESTOR Athero Imaging Head to Head IVUS Study (SATURN) | NCT00620542
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV (2015) 1.75
Cardiovascular remodelling in coronary artery disease and heart failure. Lancet (2014) 1.47
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
Non-cardiovascular effects associated with statins. BMJ (2014) 1.24
Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring) (2013) 1.04
Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov (2016) 1.02
Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol (2013) 0.99
Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care (2012) 0.97
Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol (2012) 0.96
Imaging Atherosclerosis. Circ Res (2016) 0.95
Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine (2016) 0.95
Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord (2012) 0.94
ST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosis. Int J Cardiovasc Imaging (2014) 0.92
Potential quantitative magnetic resonance imaging biomarkers of coronary remodeling in older hypertensive patients. Arterioscler Thromb Vasc Biol (2012) 0.90
Beyond vascular inflammation--recent advances in understanding atherosclerosis. Cell Mol Life Sci (2015) 0.90
Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med (2013) 0.88
Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering. Stem Cells (2012) 0.87
How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines? Arch Med Sci (2012) 0.87
Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective. Indian Heart J (2015) 0.86
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). BMJ Open (2015) 0.85
Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels. J Atheroscler Thromb (2016) 0.84
Effects of respiratory motion on coronary wall MR imaging: a quantitative study of older adults. Int J Cardiovasc Imaging (2013) 0.84
Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. J Am Heart Assoc (2013) 0.83
Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment. Neth Heart J (2017) 0.83
The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report. BMC Cardiovasc Disord (2015) 0.83
Imaging plaques to predict and better manage patients with acute coronary events. Circ Res (2014) 0.82
Macrophages, dendritic cells, and regression of atherosclerosis. Front Physiol (2012) 0.82
Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. Clinicoecon Outcomes Res (2015) 0.82
Regression of atherosclerosis: insights from animal and clinical studies. Ann Glob Health (2013) 0.80
Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. J Lipid Res (2015) 0.80
The prevention and regression of atherosclerotic plaques: emerging treatments. Vasc Health Risk Manag (2012) 0.80
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome. Int J Cardiovasc Imaging (2013) 0.80
Characteristics of plaque progression detected by serial coronary computed tomography angiography. Heart Vessels (2013) 0.80
The year in cardiology 2015: prevention. Eur Heart J (2016) 0.79
Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. Heart Vessels (2014) 0.79
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc Disord (2014) 0.79
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian J Med Res (2013) 0.79
Intravascular ultrasound and optical coherence tomography imaging of coronary atherosclerosis. Int J Cardiovasc Imaging (2015) 0.79
Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart Vessels (2013) 0.78
Current Perspectives on rosuvastatin. Integr Blood Press Control (2013) 0.78
Effects of High Fat Feeding and Diabetes on Regression of Atherosclerosis Induced by Low-Density Lipoprotein Receptor Gene Therapy in LDL Receptor-Deficient Mice. PLoS One (2015) 0.78
Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 diabetes. Diabetes Care (2012) 0.78
Positron emission tomography imaging for vascular inflammation evaluation in elderly subjects with different risk factors for cardiovascular diseases. Am J Nucl Med Mol Imaging (2014) 0.78
Long non-coding RNAs expression profile in HepG2 cells reveals the potential role of long non-coding RNAs in the cholesterol metabolism. Chin Med J (Engl) (2015) 0.78
Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. Cardiovasc Diagn Ther (2015) 0.77
The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. Eur Heart J Cardiovasc Imaging (2014) 0.77
Plaque regression and plaque stabilisation in cardiovascular diseases. Indian J Endocrinol Metab (2013) 0.77
Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with Coronary Plaque Regression. Arq Bras Cardiol (2015) 0.77
Imaging of cardiovascular complications in patients with systemic lupus erythematosus. Lupus (2015) 0.76
The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects. Clin Exp Nephrol (2012) 0.76
Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: possible role in high-glucose-induced atherogenic process. J Diabetes Res (2015) 0.76
Statin of Preference to Treat Dyslipidaemia in Patients with Renal Dysfunction: Cues from (SATURN). Sultan Qaboos Univ Med J (2012) 0.75
Bone marrow endothelial progenitors in atherosclerotic plaque resolution. Organogenesis (2013) 0.75
Lipid Lowering Therapy to Modify Plaque Microstructures. J Atheroscler Thromb (2017) 0.75
Are there differences in LDL-C target value attainment in Austrian federal states? Yes! Wien Med Wochenschr (2013) 0.75
Coronary Plaque Progression and Regression in Asymptomatic African American Chronic Cocaine Users With Obstructive Coronary Stenoses: A Preliminary Study. J Addict Med (2017) 0.75
Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study. Int J Cardiovasc Imaging (2016) 0.75
Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding. Curr Cardiol Rev (2016) 0.75
Cardiac autonomic testing and treating heart disease. "A clinical perspective". Heart Int (2014) 0.75
Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol (2016) 0.75
Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. Cardiovasc Diagn Ther (2016) 0.75
The Effect of Statin Therapy on Coronary Plaque Composition Using Virtual Histology Intravascular Ultrasound: A Meta-Analysis. PLoS One (2015) 0.75
Stabilization of high-risk plaques. Cardiovasc Diagn Ther (2016) 0.75
Rare case of proximal coronary plaque regression after distal arterial grafting. Indian Heart J (2016) 0.75
Characterization of coronary atherosclerosis by intravascular imaging modalities. Cardiovasc Diagn Ther (2016) 0.75
[Not Available]. Praxis (Bern 1994) (2012) 0.75
Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Indian Heart J (2016) 0.75
Intensive statin therapy in India: Demonstrating efficacy and safety. Indian Heart J (2016) 0.75
Representation of older adults in the late-breaking clinical trials American Heart Association 2011 Scientific Sessions. J Am Coll Cardiol (2012) 0.75
Impact of statins therapy on morphological changes in lipid-rich plaques stratified by 10-Year framingham risk score: A serial optical coherence tomography study. Oncotarget (2017) 0.75
Atherosclerosis: Coronary effects of intensive statins. Nat Rev Cardiol (2011) 0.75
Coronary CT Angiography: Variability of CT Scanners and Readers in Measurement of Plaque Volume. Radiology (2016) 0.75
Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia. J Lipid Res (2016) 0.75
The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. Hawaii J Med Public Health (2017) 0.75
Impact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease. Acta Cardiol Sin (2016) 0.75
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc Diagn Ther (2017) 0.75
Comparison of coronary arterial lumen dimensions on angiography and plaque characteristics on optical coherence tomography images and their changes induced by statin. BMC Med Imaging (2016) 0.75
Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Int J Clin Pract (2016) 0.75
Pericoronary adipose tissue ratio is a stronger associated factor of plaque vulnerability than epicardial adipose tissue on coronary computed tomography angiography. Heart Vessels (2017) 0.75
Quantification of the focal progression of coronary atherosclerosis through automated co-registration of virtual histology-intravascular ultrasound imaging data. Int J Cardiovasc Imaging (2016) 0.75
Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. Drug Des Devel Ther (2017) 0.75
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. Curr Treat Options Cardiovasc Med (2017) 0.75
Almanac 2013: stable coronary artery disease. Wien Klin Wochenschr (2013) 0.75
Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease. Heart Vessels (2016) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA (2009) 8.56
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med (2009) 6.89
T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 6.23
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol (2010) 5.79
Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA (2005) 5.50
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2003) 5.43
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med (2003) 4.61
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation (2002) 4.31
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem (2008) 4.08
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Medical device recalls and the FDA approval process. Arch Intern Med (2011) 4.01
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care (2005) 3.96
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 3.93
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol (2012) 3.91
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med (2010) 3.79
Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 3.69
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol (2006) 3.54
Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res (2008) 3.47
Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med (2006) 3.38
Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38
Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med (2013) 3.30
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA (2007) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol (2009) 3.09
Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med (2013) 3.09
Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2006) 3.01
Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation (2006) 2.93
Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med (2012) 2.92
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol (2009) 2.91
Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol (2010) 2.90
Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med (2009) 2.85
Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol (2011) 2.83
Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res (2007) 2.66
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med (2007) 2.54
Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation (2008) 2.52
Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol (2009) 2.50
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol (2004) 2.46
Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation (2011) 2.45
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42